tabrecta 150mg film tableta
"novartis pharma services ag" dio stranog druŠtva podgorica - kapmatinib - film tableta - 150mg
tabrecta 200mg film tableta
"novartis pharma services ag" dio stranog druŠtva podgorica - kapmatinib - film tableta - 200mg
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. pogledajte odjeljke 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
zoladex la 10.8mg implant u napunjenom injekcionom špricu
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - goserelin - implant u napunjenom injekcionom špricu - 10.8mg
tetavax, suspenzija za injekciju u napunjenoj štrcaljki, cjepivo protiv tetanusa, adsorbirano
sanofi pasteur, 14 espace henry vallee, lyon, francuska - toksoid tetanusa - suspenzija za injekciju u napunjenoj štrcaljki - 1 doza = 0,5 ml - urbroj: jedna doza (0,5 ml) sadrži: toksoid tetanusa ≥ 40 iu adsorbiran na aluminijev hidroksid, hidrirani 0,6 mg al
tetavax ≥ 40 i.j./0.5 ml suspenzija za injekciju u napunjenom špricu
amicus pharma d.o.o. - tetanus toksoid - suspenzija za injekciju u napunjenom špricu - ≥ 40 i.j./0.5 ml - 0,5 ml (1 doza) suspenzije za injekciju u napunjenom špricu sadrži: ≥ 40 i.u. toksoid tetanusa
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastična sredstva - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
ytracis
cis bio international - yttrium (90y) chloride - radionuklidno slikanje - dijagnostički radiofarmaceutici - upotrebljava se samo za radio-obilježavanje molekula nosača koji su posebno razvijeni i odobreni za radioaktivno obilježavanje s ovim radionuklidom. radiopharmaceutical precursor - not intended for direct application to patients.
nebilet plus 5 mg/12,5 mg filmom obložene tablete
berlin-chemie menarini hrvatska d.o.o., horvatova 80a, zagreb, hrvatska - nebivololklorid hidroklorotiazid - filmom obložena tableta - 5 mg + 12,5 mg - urbroj: jedna tableta nebileta plus 5 mg / 12,5 mg sadrži 5 mg nebivolola (u obliku nebivololklorida: 2,5 mg srrr-nebivolola ili d-nebivolola i 2,5 mg rsss-nebivolola ili l-nebivolola) i 12,5 mg hidroklorotiazida
nebilet plus 5 mg/25 mg filmom obložene tablete
berlin-chemie menarini hrvatska d.o.o., horvatova 80a, zagreb, hrvatska - nebivololklorid hidroklorotiazid - filmom obložena tableta - 5 mg + 25 mg - urbroj: jedna tableta nebileta plus 5 mg / 25 mg sadrži 5 mg nebivolola (u obliku nebivololklorida: 2,5 mg srrr-nebivolola ili d-nebivolola i 2,5 mg rsss-nebivolola ili l-nebivolola) i 25 mg hidroklorotiazida